Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-002358
Filing Date
2025-05-15
Accepted
2025-05-15 09:58:26
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9129
  Complete submission text file 0000902664-25-002358.txt   10837
Mailing Address 9 WEST 57TH STREET 36TH FLOOR NEW YORK NY 10019
Business Address 9 WEST 57TH STREET 36TH FLOOR NEW YORK NY 10019 (212) 390-9100
D1 Capital Partners L.P. (Filed by) CIK: 0001747057 (see all company filings)

EIN.: 822247965 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Subject) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94231 | Film No.: 25949493
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)